Cargando…

Conservative Surgery in Endometrial Cancer

Endometrial cancer (EC) is the sixth most common female cancer worldwide. The median age of diagnosis is 65 years. However, 4% of women diagnosed with EC are younger than 40 years old, and 70% of these women are nulliparous. These data highlight the importance of preserving fertility in these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallo, Alessandra, Catena, Ursula, Saccone, Gabriele, Di Spiezio Sardo, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745528/
https://www.ncbi.nlm.nih.gov/pubmed/35011924
http://dx.doi.org/10.3390/jcm11010183
_version_ 1784630366897700864
author Gallo, Alessandra
Catena, Ursula
Saccone, Gabriele
Di Spiezio Sardo, Attilio
author_facet Gallo, Alessandra
Catena, Ursula
Saccone, Gabriele
Di Spiezio Sardo, Attilio
author_sort Gallo, Alessandra
collection PubMed
description Endometrial cancer (EC) is the sixth most common female cancer worldwide. The median age of diagnosis is 65 years. However, 4% of women diagnosed with EC are younger than 40 years old, and 70% of these women are nulliparous. These data highlight the importance of preserving fertility in these patients, at a time when the average age of the first pregnancy is significantly delayed and is now firmly established at over 30 years of age. National Comprehensive Cancer Network (NCCN guidelines state that the primary treatment of endometrial endometrioid carcinoma, limited to the uterus, is a total hysterectomy, bilateral salpingo-oophorectomy and surgical staging. Fertility-sparing treatment is not the standard of care, and patients eligible for this treatment always have to undergo strict counselling. Nowadays, a combined approach consisting of hysteroscopic resection, followed by oral or intrauterine-released progestins, has been reported to be an effective fertility-sparing option. Hysteroscopic resection followed by progestins achieved a complete response rate of 95.3% with a recurrence rate of 14.1%. The pregnancy rate in women undergoing fertility-sparing treatment is 47.8%, but rises to 93.3% when only considering women who tried to conceive during the study period. The aim of the present review is to provide a literature overview reflecting the current state of fertility-sparing options for the management of EC, specific criteria for considering such options, their limits, the implications for reproductive outcomes and the latest research trends in this direction.
format Online
Article
Text
id pubmed-8745528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87455282022-01-11 Conservative Surgery in Endometrial Cancer Gallo, Alessandra Catena, Ursula Saccone, Gabriele Di Spiezio Sardo, Attilio J Clin Med Review Endometrial cancer (EC) is the sixth most common female cancer worldwide. The median age of diagnosis is 65 years. However, 4% of women diagnosed with EC are younger than 40 years old, and 70% of these women are nulliparous. These data highlight the importance of preserving fertility in these patients, at a time when the average age of the first pregnancy is significantly delayed and is now firmly established at over 30 years of age. National Comprehensive Cancer Network (NCCN guidelines state that the primary treatment of endometrial endometrioid carcinoma, limited to the uterus, is a total hysterectomy, bilateral salpingo-oophorectomy and surgical staging. Fertility-sparing treatment is not the standard of care, and patients eligible for this treatment always have to undergo strict counselling. Nowadays, a combined approach consisting of hysteroscopic resection, followed by oral or intrauterine-released progestins, has been reported to be an effective fertility-sparing option. Hysteroscopic resection followed by progestins achieved a complete response rate of 95.3% with a recurrence rate of 14.1%. The pregnancy rate in women undergoing fertility-sparing treatment is 47.8%, but rises to 93.3% when only considering women who tried to conceive during the study period. The aim of the present review is to provide a literature overview reflecting the current state of fertility-sparing options for the management of EC, specific criteria for considering such options, their limits, the implications for reproductive outcomes and the latest research trends in this direction. MDPI 2021-12-29 /pmc/articles/PMC8745528/ /pubmed/35011924 http://dx.doi.org/10.3390/jcm11010183 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gallo, Alessandra
Catena, Ursula
Saccone, Gabriele
Di Spiezio Sardo, Attilio
Conservative Surgery in Endometrial Cancer
title Conservative Surgery in Endometrial Cancer
title_full Conservative Surgery in Endometrial Cancer
title_fullStr Conservative Surgery in Endometrial Cancer
title_full_unstemmed Conservative Surgery in Endometrial Cancer
title_short Conservative Surgery in Endometrial Cancer
title_sort conservative surgery in endometrial cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745528/
https://www.ncbi.nlm.nih.gov/pubmed/35011924
http://dx.doi.org/10.3390/jcm11010183
work_keys_str_mv AT galloalessandra conservativesurgeryinendometrialcancer
AT catenaursula conservativesurgeryinendometrialcancer
AT sacconegabriele conservativesurgeryinendometrialcancer
AT dispieziosardoattilio conservativesurgeryinendometrialcancer